LUCA
(Lung Cancer)
qPCR SNP Detection Kit
Description
Analysed genes are responsible for production of proteins that inhibit the growth and reproduction of damaged cells, as well as regulate the aging process of cells and the binding of harmful substances entering the lungs, including nicotine. Abnormalities in the indicated genes result in the formation of a protein that does not respond to DNA damage, increases the negative effects of smoking and the risk of addiction to nicotine, thus leading to a much greater risk of respiratory cancer.
REF. NUMBER
755SNP451plu
PREDISPOSITION
Lung Cancer
ANALYSED GENES
CHRNA3, CDKN1A
IDENTIFIED POLYMORPHISMS
rs1051730, rs1801270
KIT CONTENTS
2 × Nuclease-Free Water
2 × 2xSNP MasterMix
2 × Oligos Set
2 × Positive Control Set
QUANTITY
100 rxns
STORAGE CONDITIONS
-25°C to -15°C
CERTIFICATES
More Information
Did you know...?
Lung cancer is the second most common cancer in men and women after prostate and breast cancer, respectively. This type of cancer is more common in men. 70 years old is an average age of diagnosis. Lung cancer is the leading cause of deaths from cancer in the world. The major cause of lung cancer is tobacco smoking. According WHO about 2.2 million cases of lung cancer were estimated to have occurred in 2020. Almost 1.8 million people died from lung cancer in 2020.
What may happen?
A positive family history of lung cancer and genetic polymorphism are of great significance in the development of the disease. The CHRNA3 and CDKN1A genes are associated with lung cancer. Research suggests that the presence of the mutation in CHRNA3 gene causes a reduced sensitivity of the body to plasma nicotine levels, which leads to increased consumption of tobacco and thus higher doses of toxic and carcinogenic substances contained in cigarettes. A mutation in the CDKN1A gene results in a modification of the structure of a protein that plays a role in the development of lung cancer.
How the test is performed?
The CHRNA3 and CDKN1A genes are DNA fragments containing instructions for building proteins that play a role in lung cancer development. The performed test concerns specific positions in both genes, where changes (mutations) can occur. The real-time PCR method is used to genes analysis. The technique used allows for efficient determination of the patient’s genotype in a short time and thus determining the risk of the disease.
How will the client benefit?
The test we offer allows you to determine the genotype of the tested patient in a short time and with the small amount of work. Analysis of the results based on the matrix contained in the IFU product, provides clear information about the patient’s gene variant and allows you to provide individual recommendations to the patient depending on the examined polymorphism.
Why is it worth doing a genetic test?
Due to the growing number of cases and deaths due to lung cancer, more and more patients decide to undergo genetic testing. Early detection of the disease gives a chance for effective treatment, which is why many patients want to know the individual risk of cancer development in order to implement prevention in advance.
What can be done after the test result?
In the case of an unfavorable variant of the gene, it is important to follow the recommendations and consult a doctor. It should be remembered that a normal genotype does not exclude the disease. The great potential of genetic testing makes it possible to predict many diseases and gives a chance to take action to improve health.